Neogen Corporation (NEOG) Earnings: Q1 Fiscal 2027 Results and Next Report Date

The quarter ended August 31, 2026 and Neogen published the results on October 6, 2026. Revenue and diluted EPS are shown against Q1 fiscal 2026, the same quarter a year earlier, which takes seasonal swings out of the comparison. Neogen reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Neogen's fiscal year ends May 31, so Q1 fiscal 2027 covers June through August 2026.
• The year-ago quarter included a $76.4 million gain on the sale of Neogen's Cleaners & Disinfectants business, which is why GAAP net income was $36.3 million then.
• Neogen has agreed to sell its Genomics business to Zoetis for $160.0 million. Genomics Services revenue is still in both segments until the sale closes.

Source: Neogen Q1 fiscal 2027 results, October 6, 2026. Also in the Form 10-Q for the quarter ended August 31, 2026. Figures as reported; checked against the release on November 10, 2026.

How Neogen splits revenue in its own release, under its own labels, for Q1 fiscal 2027 against Q1 fiscal 2026. Indented lines are parts of the line above them.

• Neogen's Food Safety revenue was $163 million in Q1 fiscal 2027, up 7% from $152 million in Q1 fiscal 2026, 73% of total revenue.
• Neogen's Animal Safety revenue was $59.6 million in Q1 fiscal 2027, up 4% from $57.1 million in Q1 fiscal 2026, 27% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q1 fiscal 2027 release, Neogen said:

“The Company is increasing its financial guidance for fiscal year 2027 and is now expecting total revenue in the range of $885 million to $890 million and Adjusted EBITDA in the range of $181 million to $183 million.”

Source: Neogen Q1 FY27 release, Oct 6, 2026.

This is the company's own guidance as of Oct 6, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the NEOG forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release.

Neogen's next report is expected around January 7, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q1 fiscal 2027 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q1 fiscal 2027 (this page), reported Oct 6, 2026

Neogen reports two segments. Food Safety brought in $163.2 million of the $222.8 million total in Q1 fiscal 2027 and Animal Safety $59.6 million. The largest product line, Indicator Testing & Culture Media, which includes Petrifilm, grew to $85.6 million from $76.8 million, and Bacterial & General Sanitation, which includes pathogen detection, rose to $44.6 million from $41.6 million. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

Neogen's Food Safety segment sells diagnostic test kits, culture media and related products to food and feed producers, processors, laboratories and regulators, to detect pathogens, spoilage organisms, natural toxins, allergens and sanitation problems. Royalties on licensed technology, mainly in allergen and pathogen products, generally run 2% to 10% of the revenue on those products. (Neogen Form 10-K, fiscal 2026, Jul 30, 2026)

Total revenue grew 6.5%, and core revenue, which excludes currency and divestitures or discontinued lines from the last 12 months, grew 8.1%. Neogen said about 3% of that core growth came from distributor inventory adjustments in the prior-year quarter and the timing of some customer orders this quarter. Animal Safety grew 4.2%, with core growth of 8.0%, led by Veterinary Instruments & Consumables and insect control products. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

Revenue was split almost evenly by geography: $110.1 million domestic and $112.7 million international. Neogen said every region grew, with double-digit growth in Asia Pacific. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

Neogen agreed on March 2, 2026 to sell its Genomics business to Zoetis for $160.0 million. Genomics Services revenue was $6.7 million in Food Safety and $17.3 million in Animal Safety this quarter. Australian and New Zealand competition regulators moved their reviews into a second phase in July 2026, and Neogen expects the reviews to conclude by the end of December 2026. (Neogen Form 10-Q, Q1 FY27, Oct 7, 2026; Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

Neogen lost $11.9 million on a GAAP basis in Q1 fiscal 2027, or $(0.05) per diluted share, while Adjusted Net Income was $17.5 million, or $0.08 per share. The largest adjustment is $22.3 million of amortization of acquisition-related intangibles. Neogen also adds back $5.6 million of Petrifilm duplicate manufacturing costs, $5.1 million of transformation costs and $3.1 million of share-based compensation, less a $7.4 million tax effect. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

The year-ago GAAP EPS of $0.17 included a $76.4 million gain on the sale of the Cleaners & Disinfectants business. Interest is a large cost line: net interest expense was $13.8 million, down from $15.5 million, as Neogen keeps paying down debt. It prepaid $20.0 million of its Term Loan in the quarter and another $10.0 million in September 2026. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026; Neogen Form 10-Q, Q1 FY27, Oct 7, 2026)

Weighted average shares were 218.1 million, against 217.2 million a year earlier. Neogen bought back no shares in the quarter, and 5,900,000 shares remain available under its repurchase program. (Neogen Form 10-Q, Q1 FY27, Oct 7, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Neogen gives a full-year outlook for revenue and Adjusted EBITDA in its release. With Q1 fiscal 2027 results it raised fiscal 2027 revenue guidance to $885 million to $890 million, from $880 million to $885 million, and Adjusted EBITDA to $181 million to $183 million, from $180 million to $182 million. It does not give an EPS outlook and says it cannot reconcile the Adjusted EBITDA figure to forecast net income. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

The other dated item in Neogen's plan is Petrifilm: it expects to begin a multi-quarter transfer of Petrifilm manufacturing to its Lansing site in November 2026, after validating its first SKU in August 2026. (Neogen Q1 FY27 release (Form 8-K, Exhibit 99.1), Oct 6, 2026)

A consensus figure is the average of the models published by the analysts who cover Neogen, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Neogen's own release and filings put weight on for Q1 fiscal 2027, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning NEOG is on is NEOG a buy or a sell?, what analysts expect next is on the NEOG forecast, and what the company does is on the Neogen Corporation (NEOG) stock page.

Every number on this page can be traced to a document Neogen published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.